PDS Biotech to Release Q1 2024 Financial Results on May 15, 2024

PRINCETON, N.J., May 07, 2024 -- PDS Biotechnology Corporation (Nasdaq: PDSB), a late-stage immunotherapy enterprise, is set to disclose its financial results for the first quarter of 2024, along with a business update, on Wednesday, May 15, 2024, prior to market opening. The press release will be available on the Investor Relations section of the Company's website.

In addition, PDS Biotech plans to host a Key Opinion Leader (KOL) Event on Wednesday, May 8, 2024, at 1:30 pm ET. The event's focus will be on discussing positive data updates from the VERSATILE-002 Phase 2 clinical trial involving Versamune® HPV combined with KEYTRUDA® (pembrolizumab) (NCT04260126), as well as outlining the next steps for Versamune® HPV and PDS01ADC.

The KOL event will feature Dr. Jared Weiss, M.D., Section Chief of Thoracic and Head/Neck Oncology, and Professor of Medicine at the University of North Carolina. Dr. Weiss, who is also the Principal Investigator of the VERSATILE-002 clinical trial, will present and discuss the trial's results. Dr. Robert Haddad, M.D., Professor of Medicine at Harvard Medical School and Dana-Farber Cancer Institute, will address the unmet needs in HPV-positive head and neck squamous cell cancer. The event will be moderated by Kirk Shepard, M.D., Chief Medical Officer of PDS Biotech, who will also present the forthcoming clinical path to registration for Versamune® HPV and PDS01ADC.

PDS Biotechnology is dedicated to pioneering immunotherapy solutions, particularly focusing on enhancing the immune system's ability to target and eradicate cancer cells and developing vaccines for infectious diseases. The Company is preparing to launch a pivotal clinical trial in 2024 to advance its lead program targeting advanced head and neck squamous cell cancers (HNSCC). This program is centered around a novel combination of IL-12 fused antibody drug conjugate PDS01ADC and the T-cell activator Versamune® HPV, in conjunction with a standard immune checkpoint inhibitor.

The Company believes that proof-of-concept data have demonstrated significant survival improvement and tumor shrinkage with this combination, highlighting favorable tolerability. PDS Biotech's innovative "inside-outside" mechanism appears promising in disrupting tumor defenses internally while generating potent and targeted killer T-cells to attack the tumor externally. Data from over 350 patients, along with ongoing clinical trials across various tumor types and standard treatments, support the potential broad applicability of both platforms.

Additionally, PDS Biotech's Infectimune® based vaccines have shown the ability to induce strong and durable neutralizing antibody responses, as well as potent T-cell responses, including long-lasting memory T-cells, in pre-clinical studies. For further information, please visit the company's website.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!